Pyrazinamide News and Research

RSS

Weill Cornell Medicine receives $17.4 million grant to shorten tuberculosis treatment

Researchers at Weill Cornell Medicine have received a $17.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases to discover new approaches to shorten tuberculosis (TB) treatment, potentially making it easier for patients to complete therapy.

17 Sep 2026

Can ibuprofen improve drug-resistant tuberculosis treatment?

While ibuprofen reduced inflammatory markers in drug-resistant TB patients, it did not enhance treatment outcomes, indicating the need for further research.

3 Jul 2026

High-dose rifampicin does not improve survival in tuberculosis meningitis

Each year, 11 million people worldwide develop tuberculosis, and about 1.4 million die from it. Meningitis occurs in 1–2% of patients and is the most severe complication of tuberculosis, arising when the bacteria reach the brain.

17 Dec 2025

New clinical trial shows promise for shorter TB treatment

New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel antibiotic candidate sorfequiline (TBAJ-876), a next-generation diarylquinoline, has the potential to improve tuberculosis (TB) treatment when combined with pretomanid and linezolid in a treatment regimen known as "SPaL."

19 Nov 2025

Experimental cancer drug shows promise in boosting tuberculosis treatment

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, Johns Hopkins Medicine investigators report, based on mouse-model research of the lung-damaging disease.

21 Apr 2025

Quabodepistat combo shows promise for safer, faster tuberculosis treatment

Study highlights the safety and early bactericidal activity of quabodepistat when combined with delamanid, bedaquiline, or both, offering potential for shorter and more tolerable tuberculosis treatment regimens.

1 Dec 2024

Researchers develop four new regimens to treat people with multidrug-resistant TB meningitis

In a preliminary study with a small number of humans, rabbits and mice, researchers at Johns Hopkins Children's Center say they have developed four new regimens that have the potential to treat and save the lives of people with multidrug-resistant (MDR) tuberculous (TB) meningitis.

16 Aug 2024

Second-line treatment for drug-resistant tuberculosis is as effective as first-line medicines

Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO Centers in Haiti.

27 Feb 2024

New study reveals turmeric and Tinospora Cordifolia reduce liver injury risk in TB patients

The effectiveness of herbs and alternative medicines in preventing liver injury induced by anti-tuberculosis (anti-TB) drugs.

16 Nov 2023

New hope for TB patients as UNITE4TB launches clinical trial program

Today, UNITE4TB, an international public-private partnership striving to fast-track the development of innovative Tuberculosis (TB) treatments, announced the start of its phase 2B/C clinical trial program with the first participant enrolled at its trial site in Cape Town, South Africa.

13 Nov 2023

New TB treatments tackle the disease without wrecking your microbiome

Researchers in a study published in The Lancet Microbe examined how various tuberculosis treatment regimens affect the respiratory microbiome. They found that certain treatments control tuberculosis effectively while minimally impacting the diversity and health of the respiratory microbiome.

15 Oct 2023

Higher dose and shorter treatment of key antibiotic proven to be safe for TB patients

A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George's, University of London and results published in NEJM Evidence.

29 Aug 2023

Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

The first clinical trial of a three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.

5 Jul 2023

Real-world management and outcomes of U.S. patients treated with BpaL for rifampin-resistant tuberculosis

Researchers reported on the treatment of rifampin-resistant tuberculosis in the United States using the FDA approved bedaquiline, pretomanid, and linezolid (BPaL) therapy.

1 Jun 2023

Revolution in MDR-TB treatment: Shorter all-oral regimens

Researchers reported on the evolution of multidrug-resistant tuberculosis (MDR-TB) therapy.

6 Apr 2023

Study explores decline in tuberculosis cases during COVID-19 pandemic in the United States

Researchers analyzed a pharmacy dataset to evaluate the 20% decrease in tuberculosis cases reported in 2020 by the US National Tuberculosis Surveillance System.

21 Mar 2022

ACTG announces launch of clinical trial evaluating a three-month TB treatment

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB).

10 Nov 2021